Elaine Heron - Biomarin Pharmaceutical Independent Director
| BMRN Stock | USD 89.49 0.86 0.97% |
Director
Dr. Elaine J. Heron, Ph.D., is an Independent Director of Biomarin Pharmaceutical Inc. Dr. Heron joined our Board in July 2002 and serves as the Chair of the Corporationrationrate Governance and Nominating Committee. Dr. Heron served as Chair and Chief Executive Officer of Amplyx Pharmaceuticals, Inc., a private early stage drug development company, from February 2009 until October 2015, and she continues to serve as member of that companys board. She is also a member of the boards of directors of Valla Sciences, Inc, a private life science tools company, and Palvella Therapeutics, a private early stage therapeutics company. From July 2001 to October 2008, Dr. Heron was Chair and Chief Executive Officer of Labcyte Inc., a private biotechnology company. Before joining Labcyte Inc., she spent six years in positions of increasing responsibility at the Applied Biosystems Group of Applera Corporationrationration, a biotechnology company, including the position of General Manager and Vice President of Sales and Marketing since 2002.
| Age | 70 |
| Tenure | 22 years |
| Professional Marks | MBA |
| Phone | 415 506 6700 |
| Web | https://www.biomarin.com |
Biomarin Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0163 % which means that it generated a profit of $0.0163 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0351 %, meaning that it created $0.0351 on every $100 dollars invested by stockholders. Biomarin Pharmaceutical's management efficiency ratios could be used to measure how well Biomarin Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Steven Paul | Alnylam Pharmaceuticals | 67 | |
| Paul Clancy | Incyte | 56 | |
| Lewis Cantley | Agios Pharm | 75 | |
| Marsha Fanucci | Alnylam Pharmaceuticals | 64 | |
| Douglass Given | Arrowhead Pharmaceuticals | 65 | |
| Jim Daly | Halozyme Therapeutics | N/A | |
| Michael Hayden | Ionis Pharmaceuticals | 66 | |
| Joseph Klein | Ionis Pharmaceuticals | 56 | |
| Alexis Borisy | Blueprint Medicines Corp | 46 | |
| Phillip Sharp | Alnylam Pharmaceuticals | 73 | |
| Ingrid Leisner | Bio Techne Corp | N/A | |
| Charles Cohen | Exelixis | 67 | |
| Kaye FosterCheek | Agios Pharm | 58 | |
| Nicholas Lydon | Blueprint Medicines Corp | 61 | |
| Alpna Seth | Bio Techne Corp | 54 | |
| David Pyott | Alnylam Pharmaceuticals | 65 | |
| Spencer Berthelsen | Ionis Pharmaceuticals | 65 | |
| George Demetri | Blueprint Medicines Corp | 61 | |
| Roeland Nusse | Bio Techne Corp | 66 | |
| Michael Bonney | Alnylam Pharmaceuticals | 59 | |
| Richard Jones | Mereo BioPharma Group | 50 | |
Management Performance
| Return On Equity | 0.0351 | ||||
| Return On Asset | 0.0163 |
Biomarin Pharmaceutical Leadership Team
Elected by the shareholders, the Biomarin Pharmaceutical's board of directors comprises two types of representatives: Biomarin Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biomarin. The board's role is to monitor Biomarin Pharmaceutical's management team and ensure that shareholders' interests are well served. Biomarin Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biomarin Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elaine Heron, Independent Director | ||
| Dennis Slamon, Director | ||
| Henry Fuchs, Executive Vice President and Chief Medical Officer | ||
| George Davis, Chief VP | ||
| Robert Hombach, Independent Director | ||
| Philip Scalzo, VP Officer | ||
| JeanJacques Bienaime, Chairman of the Board, CEO | ||
| Jeff Ajer, Executive Vice President Chief Commercial Officer | ||
| Richard Meier, Independent Director | ||
| Willard Dere, Director | ||
| Amy Wireman, Executive Officer | ||
| Jeffrey Ajer, Executive Officer | ||
| Eric Davis, Sr. VP, General Counsel and Secretary | ||
| Pierre Lapalme, Independent Chairman of the Board | ||
| Robert Baffi, Executive VP of Technical Operations | ||
| Richard Ranieri, Senior Vice President - Human Resources and Corporate Affairs | ||
| Elizabeth Anderson, Independent Director | ||
| Traci McCarty, Group Relations | ||
| Jonathan Day, Executive Science | ||
| Marni Kottle, Executive Officer | ||
| Humaira Serajuddin, Senior Officer | ||
| Brian Mueller, Chief Accounting Officer, Group VP and Controller | ||
| Liz Anderson, Director | ||
| Erin Burkhart, Group Officer | ||
| Bryan Lawlis, Independent Director | ||
| Greg Guyer, Executive Officer | ||
| Ganesh Vedantham, Senior Development | ||
| Daniel Spiegelman, CFO, Executive Vice President | ||
| Kevin Eggan, Chief Development | ||
| Yen Wing, Vice Science | ||
| Kathryn Falberg, Director | ||
| Alexander Hardy, CEO President | ||
| MBA MBA, Chairman CEO | ||
| Alan Lewis, Independent Director | ||
| David Pyott, Independent Director | ||
| Michael Grey, Independent Director |
Biomarin Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biomarin Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0351 | ||||
| Return On Asset | 0.0163 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.04 % | ||||
| Current Valuation | 16.78 B | ||||
| Shares Outstanding | 189.78 M | ||||
| Shares Owned By Insiders | 0.84 % | ||||
| Shares Owned By Institutions | 99.16 % | ||||
| Number Of Shares Shorted | 3.06 M | ||||
| Price To Earning | 220.73 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Biomarin Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Biomarin Pharmaceutical's short interest history, or implied volatility extrapolated from Biomarin Pharmaceutical options trading.
Pair Trading with Biomarin Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biomarin Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biomarin Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving against Biomarin Stock
| 0.62 | PBH | Prestige Brand Holdings Financial Report 2nd of May 2024 | PairCorr |
| 0.59 | SUPN | Supernus Pharmaceuticals Financial Report 14th of May 2024 | PairCorr |
| 0.55 | HLVX | Hillevax Financial Report 10th of May 2024 | PairCorr |
| 0.53 | KROS | Keros TherapeuticsInc Financial Report 2nd of May 2024 | PairCorr |
| 0.49 | MRUS | Merus BV Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Biomarin Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biomarin Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biomarin Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biomarin Pharmaceutical to buy it.
The correlation of Biomarin Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biomarin Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biomarin Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biomarin Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Complementary Tools for Biomarin Stock analysis
When running Biomarin Pharmaceutical's price analysis, check to measure Biomarin Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomarin Pharmaceutical is operating at the current time. Most of Biomarin Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biomarin Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomarin Pharmaceutical's price. Additionally, you may evaluate how the addition of Biomarin Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |
Is Biomarin Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.